ACCESS Newswire·Nov 10, 2026, 4:10 PM ET

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax

SNOA

Sonoma Pharmaceuticals reported total revenue of $7.2 million for the quarter ended September 30, 2026, representing a 28% increase from the prior year period.
U.S. revenue surged 93% for the quarter, while Latin American revenue grew 57%, with European revenue remaining flat.
Net loss per share improved 97% for the quarter, with the company reporting net income before taxes of $382,000 for the first time in its history.
Gross profit for the quarter reached $2.8 million, or 39% of revenue, driven by manufacturing improvements and customer mix.
Operating expenses remained stable at $2.5 million for the quarter, demonstrating operating leverage as revenue grew.
EBITDA for the quarter was positive at $447,000, compared to a loss of $220,000 in the same period last year.
For the six months ended September 30, 2026, total revenue increased 41% to $13.6 million, with U.S. revenue rising 113%.
Net loss for the six-month period was $396,000, a significant improvement from the $1.8 million loss recorded in the prior year period.
The company announced a paid co-development project with a U.S. skincare firm aiming for a potential product launch in summer 2027.
A new distribution partner in Taiwan has submitted an initial purchase order for Sonoma's wound-care products.
Sonoma expanded its commercial presence in the U.S. senior-care market and entered a new partnership with a specialized wound-care bandage company.
Cash and cash equivalents stood at $4.6 million as of September 30, 2026.
The company's balance sheet shows total assets of $17.1 million and total stockholders' equity of $6.6 million as of the end of the quarter.

Company: Sonoma Pharmaceuticals, Inc.
Keywords: Healthcare & Pharmaceutical, Earnings